Your browser is no longer supported. Please, upgrade your browser.
Settings
MNOV [NASD]
MediciNova, Inc.
Index- P/E- EPS (ttm)-0.25 Insider Own2.00% Shs Outstand47.53M Perf Week-0.71%
Market Cap208.66M Forward P/E- EPS next Y-0.51 Insider Trans-0.24% Shs Float41.96M Perf Month0.48%
Income-11.30M PEG- EPS next Q-0.09 Inst Own34.80% Short Float9.30% Perf Quarter-25.27%
Sales4.00M P/S52.16 EPS this Y-4.00% Inst Trans50.58% Short Ratio6.04 Perf Half Y-32.58%
Book/sh1.94 P/B2.16 EPS next Y-70.00% ROA-14.00% Target Price- Perf Year-22.51%
Cash/sh1.54 P/C2.73 EPS next 5Y20.00% ROE-14.70% 52W Range3.71 - 13.25 Perf YTD-20.15%
Dividend- P/FCF- EPS past 5Y1.30% ROI- 52W High-68.30% Beta1.41
Dividend %- Quick Ratio44.50 Sales past 5Y- Gross Margin- 52W Low13.21% ATR0.26
Employees9 Current Ratio44.50 Sales Q/Q- Oper. Margin- RSI (14)51.30 Volatility9.89% 5.68%
OptionableYes Debt/Eq0.00 EPS Q/Q93.60% Profit Margin- Rel Volume73.16 Prev Close3.76
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume646.26K Price4.20
Recom2.00 SMA202.02% SMA50-1.67% SMA200-21.35% Volume22,345,416 Change11.70%
Mar-10-21Initiated Maxim Group Buy $15
Mar-25-19Resumed B. Riley FBR Buy $22
Mar-28-18Initiated B. Riley FBR, Inc. Buy $22
Apr-18-17Initiated Credit Suisse Outperform
Jan-04-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
May-24-12Downgrade MLV & Co Buy → Hold
Oct-18-11Reiterated MLV Capital Buy $13 → $6
Jun-22-11Initiated Global Hunter Securities Buy $4
May-12-10Initiated Wedbush Outperform $13
Nov-12-08Reiterated Ladenburg Thalmann Buy $22 → $6
May-15-08Initiated Rodman & Renshaw Mkt Outperform $9
Jul-09-07Initiated Punk, Ziegel & Co Buy $22
Jun-21-21 06:30AM  
04:52AM  
Jun-18-21 03:23PM  
Jun-14-21 06:30AM  
Jun-07-21 06:30AM  
May-28-21 06:25AM  
May-17-21 09:04AM  
May-13-21 04:30PM  
May-05-21 08:00PM  
Apr-26-21 05:45AM  
Apr-22-21 06:30AM  
Apr-20-21 10:51AM  
Apr-19-21 06:30AM  
Apr-15-21 06:30AM  
Mar-15-21 05:35AM  
Mar-10-21 05:25PM  
10:03AM  
07:25AM  
Mar-09-21 04:00PM  
Mar-08-21 06:30AM  
Mar-03-21 07:46AM  
06:30AM  
Jan-31-21 06:00PM  
Jan-25-21 05:45AM  
04:32AM  
Jan-18-21 06:00PM  
Jan-11-21 09:30PM  
Dec-29-20 06:30AM  
Dec-15-20 06:30AM  
Nov-30-20 05:38PM  
Nov-25-20 06:30AM  
Nov-24-20 06:30AM  
Nov-12-20 10:00PM  
Oct-30-20 06:05AM  
Oct-26-20 11:47AM  
Oct-22-20 06:30AM  
Oct-21-20 06:30AM  
Oct-13-20 06:30AM  
Sep-24-20 09:24AM  
06:30AM  
Sep-23-20 10:37AM  
08:05AM  
06:30AM  
Sep-11-20 06:30AM  
Sep-02-20 11:23AM  
Sep-01-20 08:32AM  
06:30AM  
Aug-06-20 06:30AM  
Aug-04-20 07:40AM  
06:30AM  
Jul-28-20 08:13AM  
Jul-27-20 01:09PM  
06:30AM  
Jul-20-20 06:30AM  
Jul-02-20 05:47AM  
Jul-01-20 06:30AM  
Jun-26-20 08:28AM  
Jun-25-20 07:00PM  
Jun-24-20 08:07AM  
Jun-23-20 07:00PM  
Jun-12-20 12:31PM  
May-01-20 11:30AM  
Apr-27-20 10:20AM  
Apr-20-20 07:00PM  
Apr-14-20 09:20AM  
Apr-08-20 07:53AM  
06:07AM  
Mar-12-20 06:40AM  
Mar-09-20 07:00PM  
Feb-27-20 07:23AM  
Feb-25-20 08:15AM  
Feb-17-20 06:00PM  
Jan-28-20 07:12AM  
Jan-27-20 06:00PM  
Dec-04-19 06:00PM  
Nov-18-19 12:57PM  
Nov-06-19 01:50PM  
Oct-30-19 07:00PM  
Oct-28-19 06:00AM  
Oct-23-19 06:00AM  
Oct-07-19 07:00PM  
Sep-30-19 07:00PM  
Sep-19-19 03:48PM  
Sep-11-19 07:00PM  
Aug-29-19 07:00PM  
Aug-14-19 10:30AM  
Jul-30-19 07:00PM  
Jul-29-19 07:00PM  
Jul-24-19 11:00PM  
Jul-18-19 04:00PM  
02:03PM  
Jul-11-19 07:00PM  
Jun-12-19 07:00PM  
Jun-05-19 07:00PM  
May-16-19 01:14PM  
May-15-19 07:00PM  
May-09-19 10:00AM  
May-08-19 07:23AM  
May-07-19 07:00PM  
Apr-24-19 08:09AM  
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OBrien GeoffreyVice PresidentMay 19Option Exercise2.5243,318109,12248,318May 20 05:26 PM
Nagao HidekiDirectorMar 11Sale7.402,35417,42012,646Mar 15 09:30 PM
IWAKI YUICHIPresident and CEOFeb 25Option Exercise2.4686,250212,175927,350Mar 01 03:34 PM
Nagao HidekiDirectorSep 15Sale5.781,0005,78015,000Sep 16 04:32 PM
Nagao HidekiDirectorAug 06Option Exercise2.5815,00038,70016,000Aug 07 08:53 PM